## JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) Stock Analysis

This report analyzes the provided data for JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) to determine whether it's a buy, sell, or hold.  The analysis is based solely on the provided data and does not consider external market factors or sentiment.

**1. Data Preprocessing:**

The provided data has been parsed and organized into the following sections:

**1.1 Company Profile:**

| Feature          | Value                               |
|-----------------|------------------------------------|
| Symbol           | JBCHEPHARM                          |
| Company Name     | JB Chemicals & Pharmaceuticals Limited |
| Industry         | Pharmaceuticals                     |
| Listing Date     | 2003-04-29                          |
| ISIN             | INE572A01036                        |


**1.2 Market Data:**

| Metric                | Value     |
|-----------------------|------------|
| Last Price            | 1,871.50   |
| Change                | -41.75     |
| % Change              | -2.18%     |
| Previous Close        | 1,913.25   |
| Open                  | 1,916.50   |
| Close                 | 1,891.90   |
| VWAP                  | 1,894.66   |
| Week High             | 2,030.00   |
| Week Low              | 1,435.00   |
| Sector PE             | 48.69      |
| Symbol PE             | 48.69      |
| Daily Volatility (CM) | 1.79       |
| Annual Volatility (CM)| 34.2       |
| Delivery %           | 58.91%     |


**1.3 Pre-Open Market Data:**

The pre-open market showed limited activity with a final price of 1916.50, slightly higher than the previous close.  Buy orders dominated sell orders.

**1.4 Corporate Actions:**

| Ex-Date      | Purpose                                      |
|--------------|----------------------------------------------|
| 14-Aug-2024  | Dividend - Rs 6.75 Per Share                 |
| 16-Feb-2024  | Interim Dividend - Rs 5.50 Per Share          |
| 18-Sep-2023  | Face Value Split (Sub-Division) - From Rs 2 to Re 1 |
| 17-Aug-2023  | Dividend - Rs 9.25 Per Share                 |
| 17-Feb-2023  | Interim Dividend - Rs 8.50 Per Share          |
| ...           | ...                                         |  *(Further historical dividend data available)*


**1.5 Recent Announcements:** (Partial list shown for brevity)

* 18-Dec-2024: Alteration Of Capital and Fund Raising-XBRL
* 18-Dec-2024: ESOP/ESOS/ESPS
* 07-Dec-2024: Alteration Of Capital and Fund Raising-XBRL
* ... *(Further announcements available)*


**1.6 Financial Results (Last Five Quarters):**

| Quarter      | Income     | Expenditure | Profit After Tax | EPS      | Audited |
|--------------|------------|-------------|-------------------|----------|---------|
| Q3 FY2025    | 96,465     | 73,045       | 17,312            | 11.15    | No      |
| Q2 FY2025    | 95,747     | 72,326       | 17,323            | 11.16    | No      |
| Q1 FY2025    | 82,530     | 66,219       | 12,585            | 8.11     | Yes     |
| Q4 FY2024    | 80,671     | 63,030       | 12,792            | 8.25     | No      |
| Q3 FY2024    | 84,360     | 64,288       | 14,502            | 9.36     | No      |


**1.7 Shareholding Patterns:**

Promoter holding has shown a slight decrease over the last year, from 53.86% to 53.74%.

| Date        | Promoter & Promoter Group | Public |
|-------------|--------------------------|--------|
| 30-Sep-2023 | 53.86%                     | 46.14% |
| 31-Dec-2023 | 53.83%                     | 46.17% |
| 31-Mar-2024 | 53.78%                     | 46.22% |
| 30-Jun-2024 | 53.77%                     | 46.23% |
| 30-Sep-2024 | 53.74%                     | 46.26% |


**1.8 Key Directors and Contact Information:**

*(List of directors and contact details for the Registrar and company are available in the provided data but omitted here for brevity.)*


**2. Key Indicators:**

**2.1 Current Price Analysis:**

The current price is down significantly from its week high and slightly below its previous close.  The pre-open activity suggested a slightly positive sentiment, but this was not sustained during the trading session.

**2.2 Financial Performance:**

Revenue and profit after tax show some fluctuation but generally maintain a positive trend over the last five quarters. EPS also shows a similar pattern.  The most recent quarter's financial results are unaudited.

**2.3 Shareholding Analysis:**

A slight decrease in promoter holding is observed, which could be a minor negative signal, but the overall change is not significant.

**2.4 Corporate Action Summary:**

The company has a history of consistent dividend payouts, including interim dividends.  A face value split occurred in September 2023.

**2.5 Volatility and Risk:**

The stock exhibits moderate daily and annual volatility.  The delivery percentage is relatively high, suggesting some degree of investor confidence.

**3. Final Verdict:**

Based on the provided data, the recommendation is **Hold**.

**Reasoning:**

* While the financial performance shows a generally positive trend, the recent price drop and slight decrease in promoter holding introduce some uncertainty.
* The consistent dividend payouts are a positive factor.
* The moderate volatility and high delivery percentage suggest a relatively stable stock.
* The unaudited nature of the most recent quarter's financials necessitates caution.  Further confirmation is needed once audited results are released.

**Conclusion:**

JBCHEPHARM shows signs of a healthy business with consistent dividend payments. However, recent price action and a slight decrease in promoter holding warrant a cautious approach.  A "Hold" recommendation is appropriate until further information, particularly audited Q3 FY2025 results, becomes available.  More detailed analysis of the financial statements (available via the provided XBRL links) would be beneficial for a more definitive assessment.
